Group One Trading, L.P. Anavex Life Sciences Corp. Transaction History

Group One Trading, L.P.

$2.4 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $14,792 - $29,203	2,935 New	2,935 $27,000
Q2 2023 Aug 09, 2023	SELL	$7.66 - $9.5 $21,708 - $26,923	-2,834 Reduced 8.09%	32,197 $261,000
Q1 2023 May 12, 2023	SELL	$8.32 - $11.75 $1.13 Million - $1.6 Million	-136,135 Reduced 79.53%	35,031 $300,000
Q4 2022 Feb 09, 2023	SELL	$7.65 - $14.43 $125,658 - $237,027	-16,426 Reduced 8.76%	171,166 $1.58 Million
Q3 2022 Nov 09, 2022	BUY	$8.9 - $12.86 $450,010 - $650,240	50,563 Added 36.9%	187,592 $1.94 Million
Q2 2022 Aug 11, 2022	BUY	$7.31 - $12.84 $658,411 - $1.16 Million	90,070 Added 191.81%	137,029 $1.37 Million
Q1 2022 May 12, 2022	BUY	$9.74 - $17.69 $268,327 - $487,341	27,549 Added 141.93%	46,959 $578,000
Q4 2021 Feb 11, 2022	SELL	$16.88 - $23.31 $267,834 - $369,859	-15,867 Reduced 44.98%	19,410 $337,000
Q3 2021 Nov 12, 2021	SELL	$16.82 - $25.75 $1.82 Million - $2.79 Million	-108,457 Reduced 75.46%	35,277 $633,000
Q2 2021 Aug 10, 2021	BUY	$10.16 - $28.86 $1.14 Million - $3.25 Million	112,620 Added 361.96%	143,734 $3.29 Million
Q1 2021 May 12, 2021	SELL	$5.17 - $16.13 $167,352 - $522,128	-32,370 Reduced 50.99%	31,114 $465,000
Q4 2020 Feb 10, 2021	BUY	$4.01 - $7.58 $139,303 - $263,321	34,739 Added 120.85%	63,484 $343,000
Q3 2020 Nov 12, 2020	SELL	$3.8 - $5.0 $135,910 - $178,830	-35,766 Reduced 55.44%	28,745 $131,000
Q2 2020 Aug 13, 2020	SELL	$2.62 - $5.2 $15,389 - $30,544	-5,874 Reduced 8.35%	64,511 $317,000
Q1 2020 May 13, 2020	SELL	$2.38 - $5.81 $91,344 - $222,987	-38,380 Reduced 35.29%	70,385 $222,000
Q4 2019 Feb 10, 2020	SELL	$2.31 - $3.14 $22,695 - $30,850	-9,825 Reduced 8.28%	108,765 $282,000
Q3 2019 Nov 12, 2019	SELL	$2.22 - $3.9 $14,481 - $25,439	-6,523 Reduced 5.21%	118,590 $375,000
Q2 2019 Aug 09, 2019	BUY	$2.75 - $3.7 $94,107 - $126,617	34,221 Added 37.65%	125,113 $422,000
Q1 2019 May 13, 2019	SELL	$1.68 - $3.42 $96,297 - $196,034	-57,320 Reduced 38.67%	90,892 $277,000
Q4 2018 Feb 06, 2019	BUY	$1.25 - $2.75 $35,227 - $77,500	28,182 Added 23.48%	148,212 $231,000
Q3 2018 Nov 08, 2018	SELL	$2.23 - $3.82 $40,077 - $68,653	-17,972 Reduced 13.02%	120,030 $328,000
Q2 2018 Aug 14, 2018	BUY	$2.08 - $4.26 $11,656 - $23,873	5,604 Added 4.23%	138,002 $362,000
Q1 2018 May 11, 2018	BUY	$2.32 - $3.44 $89,818 - $133,179	38,715 Added 41.33%	132,398 $365,000
Q4 2017 Feb 09, 2018	BUY	$3.12 - $4.94 $53,177 - $84,197	17,044 Added 22.24%	93,683 $302,000
Q3 2017 Nov 15, 2017	BUY	$3.42 - $4.87 $204,611 - $291,362	59,828 Added 355.89%	76,639 $317,000
Q2 2017 Aug 14, 2017	BUY	N/A	16,811	16,811 $89,000

Others Institutions Holding AVXL

# of Institutions

154

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

Black Rock Inc. New York, NY

6.39M
Shares

$47.6 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.74M
Shares

$35.3 Million
0.0% of portfolio
State Street Corp Boston, MA

3.07M
Shares

$22.8 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.88M
Shares

$14 Million
0.0% of portfolio
Wealthgarden F.S. LLC El Segundo, CA

910K
Shares

$6.78 Million
0.32% of portfolio

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account